WAVE Life Sciences (WVE) Misses Q3 EPS by 17c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Pentagon reportedly locked down, hazmat teams responding
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Wave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update
November 9, 2020 7:30 AM ESTResults from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021
Dosing in three new clinical trials with novel compounds incorporating PN chemistry and targeting SNP3 in HD, C9orf72 in ALS / FTD and exon 53 skipping in DMD expected in 2021
Alpha-1 antitrypsin deficiency announced as first ADAR editing program, with potential to address both lung and... More
